- recruitingPHASE3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is looking at a new drug, daraxonrasib, for people with pancreatic cancer that has spread. It compares daraxonrasib alone, or with standard chemotherapy (gemcitabine and nab-paclitaxel), against standard chemotherapy by itself. The aim is to see if the new treatments can help people live longer and stop the cancer from growing.
United States · Australia · Austria - recruitingPHASE3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is testing a new medicine, atebimetinib, alongside standard chemotherapy for pancreatic cancer that has spread. We want to see if this combination works better and is safe for patients who haven't had treatment before.
United States · Australia · Georgia - recruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
This study is for people who have had surgery for pancreatic cancer. We are testing a new drug, daraxonrasib, to see if it can stop the cancer from coming back, compared to just being watched. It's to help see if this new treatment works better.
United States · France · Germany - recruitingPHASE3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
This study is testing a new drug called zoldonrasib, combined with standard chemotherapy, for people with pancreatic cancer that has spread. It compares this combination to chemotherapy alone, to see if it helps people live longer or stops the cancer from growing for longer. It focuses on a specific type of cancer gene.
United States · United Kingdom - active not recruitingPHASE3
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
This study is looking for a new treatment for pancreatic cancer that has spread. It compares a new medicine called RMC-6236 with standard chemotherapy for people whose cancer has already been treated once before. The aim is to see if the new medicine is safer and works better.
United States · France · Germany - recruiting
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Researchers are developing a breath test for pancreatic cancer. This test looks for tiny chemicals in your breath that might change when pancreatic cancer is present. The goal is to help doctors find pancreatic cancer earlier, especially in people with unclear symptoms, so treatment can start sooner.
United Kingdom - recruiting
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
We're testing a new breath test to find pancreatic cancer earlier. This is important because pancreatic cancer can be hard to spot early. The test looks for special smells on your breath that might be linked to the cancer. Finding it sooner could mean more treatment choices and better health outcomes.
United Kingdom